Paperonium

Muscle disease · Neurology · 2026

Summary: boys’ 12-month weight-for-height rise is bigger on one steroid than another. That’s the 6-month result.

The summary, 12 monthsclearly higher weight-for-heightThe paper’s table, 6 months, thesame three numbersThe paper’s table, 12 monthsunder half, could be zero0.570.240.9−0.04 to 0.520 points0.20.40.60.81no difference between the drugs
The summary,12 monthsclearly higherweight-for-heightThe paper’s table,6 months, the samethree numbersThe paper’s table,12 monthsunder half, couldbe zero0.570.240.9−0.040.52−0.500.51no difference betweenthe drugspoints

How much more boys’ weight-for-height score rose on vamorolone than on prednisone

The paper says

Boys with Duchenne, a muscle-wasting disease, are treated with steroids, and weight gain is a main worry. The paper’s summary says that over 12 months, boys’ weight-for-height score rose 0.57 more on the steroid vamorolone than on prednisone (a range of 0.24 to 0.90).

Its own data show

The paper’s table gives exactly those numbers for 6 months. For 12 months it gives 0.24, a range of −0.04 to 0.52: under half as big, possibly zero. Its discussion agrees: a bigger rise at 6 months, not at 12. The online paper still shows 0.57; a July 2026 correction notice could not be read.

The score is a boy’s BMI, his weight for his height, compared with typical boys his age; 0 is average. The range spans the values the data allow; one dipping below 0 means there may be no difference. Summary-only readers, and reviews that copy summaries, see a clear 12-month weight-for-height gap the data don’t show.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

Vamorolone for Duchenne Muscular Dystrophy · Neurology (2026) · doi:10.1212/WNL.0000000000214756